Market revenue in 2023 | USD 1.4 million |
Market revenue in 2030 | USD 3.3 million |
Growth rate | 13.1% (CAGR from 2023 to 2030) |
Largest segment | Spinal muscular atrophy |
Fastest growing segment | Sickle Cell Disease |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Spinal Muscular Atrophy, Cystic Fibrosis, Tay-Sachs, Gaucher Disease, Sickle Cell Disease, Other Medical Conditions |
Key market players worldwide | Myriad Genetics Inc, Illumina Inc, Thermo Fisher Scientific Inc, Roche Holding AG, Labcorp Holdings Inc, Centogene NV Ordinary Shares, Danaher Corp, Otogenetics, MedGenome, Roche Holding AG ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to carrier screening market will help companies and investors design strategic landscapes.
Spinal muscular atrophy was the largest segment with a revenue share of 35.71% in 2023. Horizon Databook has segmented the Australia carrier screening market based on spinal muscular atrophy, cystic fibrosis, tay-sachs, gaucher disease, sickle cell disease, other medical conditions covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia carrier screening market, including forecasts for subscribers. This country databook contains high-level insights into Australia carrier screening market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account